Prelude Capital Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Prelude Capital Management, LLC
- $934 Million
- Q2 2025
A detailed history of Prelude Capital Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 18,328 shares of CRNX stock, worth $787,004. This represents 0.06% of its overall portfolio holdings.
Number of Shares
18,328
Previous 12,959
41.43%
Holding current value
$787,004
Previous $434,000
21.43%
% of portfolio
0.06%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
240Shares Held
91.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.17MShares$394 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$275 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$268 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$249 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$240 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.31B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...